Who may be eligible for the Clinical Study for AL-CM trial?

Inclusion Criteria: * Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine; * Patients have the ability to understand the test, can cooperate with investigators. Exclusion Criteria: * Unable to understand or unwilling to fill in informed consent forms or follow visitors

ClinicalTrials.gov record NCT04924998

Clinical Study for AL-CM

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.The registry record was last updated on Jan 31, 2023, about 3 years ago, so the status shown may be out of date. The study team or the registry can confirm.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

AgeSee eligibility The registry's age field and its own written criteria give different ages for this study. Check the full criteria below and ask the study team.

SexAll

LocationChina

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This is a prospective observational study of people diagnosed with Immunoglobulin Light Amyloidosis Cardiomyopathy (AL-CM). It observes current treatments and follows participants long-term to record outcomes. The study will track major cardiovascular events (cardiovascular death, myocardial infarction, stroke, and hospitalized unstable angina) over a 10-year timeframe.

What it is studying. The study is observing how current treatments for AL-CM relate to long-term outcomes, specifically measuring the incidence of major cardiovascular events (MACE-4: cardiovascular death, myocardial infarction, stroke, hospitalized unstable angina) over 10 years.

What the researchers hope to learn. To observe treatment patterns and conduct long-term follow-up in AL-CM, and to measure 10-year incidences of major cardiovascular events (MACE-4).

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Drug: current treatment of AL-CM

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
Patients have the ability to understand the test, can cooperate with investigators.

Exclusion criteria

Unable to understand or unwilling to fill in informed consent forms or follow visitors

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants continue their current treatment while the study observes outcomes and follows them over time. You would be asked to give informed consent and to cooperate with investigators during scheduled follow-up contacts or visits. The study will record health events, especially major cardiovascular events (cardiovascular death, myocardial infarction, stroke, and hospitalized unstable angina), with follow-up lasting up to 10 years.

How the study is structured. A prospective, observational cohort study. Participants continue their usual/current treatment (treatments are not assigned by the study) while the study team collects data and follows health outcomes over time.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in China. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on AL amyloidosis

Clinical trials69 trials listed for AL amyloidosisEvery trial the registry lists for AL amyloidosis, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in AL amyloidosis researchLatest monthly update: September 2026. Includes: Daratumumab alone. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: Jun 1, 2021
Primary completion: Jun 1, 2031 (estimated)
Study completion: Jun 1, 2031 (estimated)
Target enrollment: 400 participants (estimated)
Last updated on registry: Jan 31, 2023
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Participating sites (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University, ChinaRecruiting
Hangzhou, Zhejiang · China
- xiaohong U PAN · +8613857116993

Terms used on this page · explanations by MedicalUpdates.ai

long-term follow-up: Observation that continues for years after the study treatment, often required for gene and cell therapies.
informed consent: The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials